Details

Zavarovanje stanovanjskih objektov in premičnin : diplomsko delo
ID Arnež, Marjetka (Author), ID Pevcin, Primož (Mentor) More about this mentor... This link opens in a new window

.pdfPDF - Presentation file, Download (4,92 MB)
MD5: BDA1B93E301DDE147ED011345CA205D2
PID: 20.500.12556/rul/ccc8b7c6-a29a-407f-8f13-05ec08acb214

Language:Slovenian
Keywords:zavarovanje, zavarovalništvo, premoženjska zavarovanja, zavarovalne premije, zavarovalnina, diplomske naloge
Work type:Undergraduate thesis
Typology:2.11 - Undergraduate Thesis
Organization:FU - Faculty of Administration
Place of publishing:Ljubljana
Publisher:[M. Arnež]
Year:2011
Number of pages:IX, 55 str.
PID:20.500.12556/RUL-22009 This link opens in a new window
UDC:368.1(043.2)
COBISS.SI-ID:3788462 This link opens in a new window
Publication date in RUL:11.07.2014
Views:3026
Downloads:361
Metadata:XML DC-XML DC-RDF
:
ARNEŽ, Marjetka, 2011, Zavarovanje stanovanjskih objektov in premičnin : diplomsko delo [online]. Bachelor’s thesis. Ljubljana : M. Arnež. [Accessed 6 April 2025]. Retrieved from: https://repozitorij.uni-lj.si/IzpisGradiva.php?lang=eng&id=22009
Copy citation
Share:Bookmark and Share

Similar documents

Similar works from RUL:
  1. ǂThe ǂimportance of cancer stem cells and epithelial-mesenchymal transition in the progression of non-small cell lung cancer
  2. Gene expression levels of the prolyl hydroxylase domain proteins PHD1 and PHD2 but not PHD3 are decreased in primary tumours and correlate with poor prognosis of patients with surgically resected non-small-cell lung cancer
  3. Study of phosphatidylethanolamine N-methyltransferase gene expression in non-small cell lung cancer tissue
  4. Usefulness of immunohistochemically determined epidermal growth factor receptor mutations in lung cancer
  5. Diabetes mellitus and physical activity
Similar works from other Slovenian collections:
  1. Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small cell lung cancer
  2. Outsourcing predictive biomarker testing in non-small cell carcinoma
  3. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
  4. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
  5. NSCLC molecular testing in Central and Eastern European countries

Back